Accelerate Diagnostics, Inc. (AXDX)

$0.7241

-0.01 (-0.81%)
Rating:
Recommendation:
Buy
Symbol AXDX
Price $0.7241
Beta 1.101
Volume Avg. 0.28M
Market Cap 71.758M
Shares () -
52 Week Range 0.46-3.74
1y Target Est -
DCF Unlevered AXDX DCF ->
DCF Levered AXDX LDCF ->
ROE 172.35% Strong Buy
ROA -92.95% Strong Sell
Operating Margin -
Debt / Equity -874.19% Strong Sell
P/E -
P/B -6.43 Strong Sell
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest AXDX news


Mr. Lawrence Mehren
Healthcare
Medical Devices
NASDAQ Capital Market

Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was incorporated in 1982 and is headquartered in Tucson, Arizona.